

**FIG. 1D**




FIG. 2B




FIG. 2C

FIG. 2D




Fig. 3A






Fig. 3B






FIG. 6

THEORETICAL

Graph of Linear Regression Analysis  
for a Selected Measurement Vector




FIG. 7




FIG. 8A





FIG. 8B



Pt. 7




FIG. 8C




FIG. 8D



FIG. 9A




FIG. 9B





FIG. 9C




FIG. 9D

Pt. 5



FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIG. 11E




FIG. 11F




FIG. 12

**Patient Clinical Data**

Patient	Sex	Infarct Location	Time from MI to EP Study (years)	Drug Therapy	VT Cycle-Length at Onset (ms)
1	M	Ant	3	Amiodarone	328
2	M	Inf-lat	11	Sotalol	368
3	M	Multiple	9	Amiodarone	432
4	M	Ant	15	Amiodarone	272
5	M	Post	5	Amiodarone	251
6	M	Multiple	12	Amiodarone + mex	473
7	M	Inf-lat	5	Amiodarone + mex	197
8	M	Inf	2	Amiodarone	401
9	M	Inf-lat	4	Amiodarone	243
10	F	Inf	1	Amiodarone	287
11	M	Inf	2	Amiodarone	252 (no reentry)
12	M	Ant	14	Sotalol	384
13	M	Ant	1	Amiodarone	249 (no reentry)
14	M	Ant	11	Amiodarone	223 (no reentry)

FIG. 13

